1. Home
  2. ALXO vs MGYR Comparison

ALXO vs MGYR Comparison

Compare ALXO & MGYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALXO
  • MGYR
  • Stock Information
  • Founded
  • ALXO 2015
  • MGYR 1922
  • Country
  • ALXO United States
  • MGYR United States
  • Employees
  • ALXO N/A
  • MGYR N/A
  • Industry
  • ALXO Biotechnology: Pharmaceutical Preparations
  • MGYR Savings Institutions
  • Sector
  • ALXO Health Care
  • MGYR Finance
  • Exchange
  • ALXO Nasdaq
  • MGYR Nasdaq
  • Market Cap
  • ALXO 81.1M
  • MGYR 77.6M
  • IPO Year
  • ALXO 2020
  • MGYR 2006
  • Fundamental
  • Price
  • ALXO $1.41
  • MGYR $13.49
  • Analyst Decision
  • ALXO Strong Buy
  • MGYR
  • Analyst Count
  • ALXO 6
  • MGYR 0
  • Target Price
  • ALXO $14.20
  • MGYR N/A
  • AVG Volume (30 Days)
  • ALXO 886.3K
  • MGYR 4.1K
  • Earning Date
  • ALXO 11-07-2024
  • MGYR 10-31-2024
  • Dividend Yield
  • ALXO N/A
  • MGYR 1.51%
  • EPS Growth
  • ALXO N/A
  • MGYR 2.51
  • EPS
  • ALXO N/A
  • MGYR 1.23
  • Revenue
  • ALXO N/A
  • MGYR $31,497,000.00
  • Revenue This Year
  • ALXO N/A
  • MGYR N/A
  • Revenue Next Year
  • ALXO N/A
  • MGYR N/A
  • P/E Ratio
  • ALXO N/A
  • MGYR $10.78
  • Revenue Growth
  • ALXO N/A
  • MGYR 4.87
  • 52 Week Low
  • ALXO $1.19
  • MGYR $9.66
  • 52 Week High
  • ALXO $17.83
  • MGYR $13.49
  • Technical
  • Relative Strength Index (RSI)
  • ALXO 47.30
  • MGYR 80.24
  • Support Level
  • ALXO $1.19
  • MGYR $12.81
  • Resistance Level
  • ALXO $1.63
  • MGYR $13.24
  • Average True Range (ATR)
  • ALXO 0.11
  • MGYR 0.20
  • MACD
  • ALXO 0.01
  • MGYR 0.09
  • Stochastic Oscillator
  • ALXO 50.00
  • MGYR 100.00

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

About MGYR Magyar Bancorp Inc.

Magyar Bancorp Inc is a mid-tier stock holding company. The Company offers a full array of commercial and retail financial services, including the taking of time, savings and demand deposits; the making of commercial, consumer and home equity loans; and the provision of other financial services. The business consists of getting retail deposits from the general public in the areas surrounding the main office in New Brunswick, New Jersey and branch offices located in Middlesex and Somerset Counties, New Jersey, and investing those deposits, together with funds generated from operations and wholesale funding, in residential mortgage loans, home equity loans, home equity lines of credit, commercial real estate loans, commercial business loans, Small Business Administration loans.

Share on Social Networks: